| Literature DB >> 17521417 |
Joanne L Fothergill1, Stavroula Panagea, Charles A Hart, Martin J Walshaw, Tyrone L Pitt, Craig Winstanley.
Abstract
BACKGROUND: Some isolates of the Liverpool cystic fibrosis epidemic strain of Pseudomonas aeruginosa exhibit an unusual virulence-related phenotype, characterized by over-production of quorum sensing-regulated exoproducts such as pyocyanin and LasA protease. Our aim was to determine the prevalence of this unusual phenotype amongst isolates of the epidemic strain, and to study other intraclonal phenotypic and genotypic variations.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17521417 PMCID: PMC1890549 DOI: 10.1186/1471-2180-7-45
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1Pyocyanin production in culture supernatants after overnight growth in Luria broth. Mean absorbance values are shown for isolates of P. aeruginosa falling into the following categories: (a) water isolates (n = 10); (b) keratitis isolates (n = 10); (c) non-LES CF isolates (n = 29); (d) all LES isolates (n = 48); (e) LES isolates omitting known lasR mutants (n = 38); (f) LES known lasR mutants (n = 10); (g) strain PA01.
Figure 2Pyocyanin assays on LES isolates. Production of pyocyanin in culture supernatants during growth of LES isolates in L-broth is shown for all the LES isolates tested in this study. Each combination of colour and shape plotted represents a different LES isolate. The only non-LES isolate included is strain PA01 (blue squares, indicated by the arrow). LES isolates could be sub-divided on the basis of pyocyanin assays into various groups: (i) OP (early- and over-production of pyocyanin) [circles]. (ii) Intermediate [diamonds]. (iii) Normal or negative [squares]
Phenotypes and genotypes of sequential LES isolates from six CF patients
| A | 1995 | B7 | I-II | + | 24.2 {4.9} | NO | R | R | R | D | D | SCV,NM,Ra,S |
| A | 1998 | B32 | I-II | - | 98.4 {7.2} | YES | S | R | S | D | S | SCV,NM,F,S |
| A | 2000 | B45 | ID-II | - | 67.3 {1.9} | nd | R | R | R | R | S | NM,F,S |
| A | 2003 | B25 | I-II | - | 98.6 {0.6} | YES | S | R | S | S | S | NM,Ra,S |
| A | 2003 | B70 | IC-II | - | 82.7 {5.1} | NO | R | R | R | S | S | M,Ra,S |
| A | 2004 | 49111 | ND | - | 98.7 {1.6} | YES | S | R | S | S | S | NM,Ra,RW |
| A | 2004 | 49074 | ND | - | 97.0 {1.5} | YES | R | R | R | S | S | NM,Ra,S |
| B | 1996 | B46 | IH-IIE | + | 81.6 {2.2} | NO | R | R | R | D | D | SCV,NM,F,S |
| B | 1998 | B38 | I-II | + | 84.8 {2.9} | NO | R | R | R | D | S | NM,Ra,S |
| B | 2003 | B60 | IE-II | + | 20.6 {1.9} | nd | R | R | R | D | S | NM,F,S |
| B | 2003 | B48 | I-II | - | 93.2 {0.9} | NO | S | R | R | S | S | M,Ra,S |
| B | 2004 | 49194 | ND | - | 93.6 {0.9} | NO | S | S | S | S | R | NM,Ra,S |
| C | 1996 | B49 | IC-II | + | 43.3 {4.4} | nd | R | R | S | S | S | SCV,NM,F,S |
| C | 1998 | B40 | I-II | + | 20.3 {2.3} | nd | S | R | S | R | S | SCV,NM,F,S |
| C | 1998 | B41 | I-II | - | 98.6 {1.3} | YES | S | R | S | D | S | NM,Ra,S |
| C | 1998 | 109 | ND | + | 82.7 {1.1} | nd | S | S | S | S | S | NM,F,S |
| C | 2003 | B64 | I-II | - | 95.2 {1.8} | NO | S | S | S | S | D | SCV,NM,F.S |
| C | 2003 | B65 | I-II | + | 8.61 {7.8} | nd | S | R | S | D | S | NM,Ra,S |
| C | 2004 | 49137 | ND | INT | 63.4 {3.4} | nd | S | S | S | D | R | SCV,NM,F,S |
| D | 1996 | B28 | IC-II | - | 41.3 {5.5} | NO | S | R | S | S | S | SCV,NM,F,S |
| D | 1998 | B35 | IC-II | INT | 96.6 {1.2} | NO | S | S | S | D | S | SCV,NM,F,S |
| D | 2002 | B61 | IC-II | NOR | 3.33 {4.4} | nd | R | R | S | R | D | NM,Ra,S |
| D | 2002 | B62 | I-IIG | - | 95.3 {5.4} | YES | S | S | S | S | S | SCV,NM,F,S |
| D | 2002 | B63 | I-II | - | 98.5 {1.9} | YES | S | R | S | R | S | NM,Ra,S |
| E | 1995 | B4 | IC-II | - | 95.2 {2.0} | YES | S | S | S | R | S | NM,Ra,S |
| E | 1995 | B57 | I-II | + | 26.8 {3.2} | NO | R | R | R | S | D | NM,Ra,S |
| E | 2000 | B50 | I-II | - | 96.4 {3.6} | NO | R | R | R | S | S | M,Ra,S |
| E | 2000 | B51 | I-II | - | 98.4 {2.6} | YES | S | S | S | R | S | SCV,NM,Ra,S |
| E | 2002 | B67 | ID-IIB | - | 98.4 {2.9} | YES | R | R | R | S | D | NM,F,S |
| F | 1996 | B30 | I-II | - | 98.5 {1.0} | YES | S | S | R | R | S | SCV,NM,Ra,S |
| F | 2000 | B55 | I-II | NOR | 34.8 {4.4} | nd | S | S | S | S | S | M,Ra,S |
| F | 2002 | B68 | IA-II | NOR | 88.5 {4.4} | nd | S | S | S | S | S | NM,F,S |
| F | 2002 | B69 | IB-IID | + | 31.6 {5.6} | nd | R | R | R | R | S | NM,F,S |
PFGE refers to pulsotypes obtained with SpeI and XbaI respectively; LasA activity indicates the percentage of the initial (time zero) A600 value remaining after 60 min; SD: standard deviation for four replicates; lasR mut. refers to whether the isolate is a confirmed lasR mutant or not by sequencing; ND: not determined; antimicrobial agent abbreviations are ceftazidime (CAZ), aztreonam (ATM), meropenem (MER), tobramycin (TOB) and ciprofloxacin (CIP); colony morphology was scored as mucoid (M), non-mucoid (NM), flat (F) raised (Ra), smooth (S), rough/wrinkled (RW), small colony variant (SCV). For OP phenotype: + indicates OP-positive; - indicates OP-negative; INT indicates intermediate; NOR indicates normal.
Figure 3Pyocyanin production by sequential isolates from CF patients A-C. Production of pyocyanin in culture supernatants during growth of LES isolates in L-broth is shown for isolates from three CF patients (patient A-F). Chronological order of isolation is indicated by colour from the earliest to the most recent in the following order : yellow (1995), red (1996), blue (1998), black (2000), green (2003) and orange (2004). Different isolates from the same year are indicated by different shapes.
Figure 4Pyocyanin production by sequential isolates from CF patients D-F. Production of pyocyanin in culture supernatants during growth of LES isolates in L-broth is shown for isolates from three CF patients (patient D-F). Chronological order of isolation is indicated by colour from the earliest to the most recent in the following order : yellow (1995), red (1996), blue (1998), black (2000) and pink (2002). Different isolates from the same year are indicated by different shapes.
Comparison between antimicrobial susceptibility and OP phenotype of LES isolates
| Antimicrobial agent | % resistant LES isolates for different OP phenotypes | ||
| OP (n = 11) | Negative (n = 17) | N or I (n = 5) | |
| CAZ R | 73 | 24 | 20 |
| ATM R | 64 | 35 | 0 |
| MER R | 91 | 65 | 20 |
| TOB R | 27 | 24 | 20 |
| TOB D | 45 | 12 | 40 |
| CIP R | 0 | 6 | 20 |
| CIP D | 27 | 12 | 20 |
CAZ, ceftazidime; ATM, aztreonam; MER, meropenem; TOB, tobramycin; CIP, ciprofloxacin; R, resistant; D, intermediate antimicrobial susceptibility; N, normal; I, intermediate OP phenotype
LES lasR mutants
| LES isolate | Comments/Reference | |
| LESB41 | deletion of CCGGGCTGGCTACG leading to divergence from position R66 onward | isolated from patient C |
| LESB30 | single point mutation leading to divergence from position S33 onward | isolated from patient F |
| LESB32 | single nucleotide insertion/frame-shift mutation leading to divergence from position L223 onward | isolated from patient A |
| LESB25 | same as LESB32 | isolated from patient A |
| LES49111 | same as LESB32 | isolated from patient A |
| LES49074 | same as LESB32 | isolated from patient A |
| LESB63 | same as LESB32 | isolated from patient D |
| LESB62 | single point mutation leading to single amino acid change H224 → R | isolated from patient D |
| LESB4 | same as LESB32 | isolated from patient E |
| LESB51 | same as LESB32 | isolated from patient E |
| LESB67 | deletion of AAGCGGAA leading to divergence from position A134 onward | isolated from patient E |
| LES49220 | single point mutation leading to single amino acid change G235 → D | CF isolate, isolated in 2004 |
| LES400 | repetition of GGTGCTC leading to divergence from G123 onward | [17] |
| LES430 | deletion of GTGGATGCTC leading to divergence from position W152 onwards | [17] |
| LESB44 | insertion of GAAG leading to divergence from position I35 onwards | [17] |